Evidence suggests that spironolactone, a nonselective mineralocorticoid receptor (MR) antagonist, modulates alcohol seeking and consumption. Therefore, spironolactone may represent a novel pharmacotherapy for alcohol use disorder (AUD). In this study, we tested the effects of spironolactone in a mouse model of alcohol drinking (drinking-in-the-dark) and in a rat model of alcohol dependence (vapor exposure). We also investigated the association between spironolactone receipt for at least 60 continuous days and change in self-reported alcohol consumption, using the Alcohol Use Disorders Identification Test-Consumption (AUDIT-C), in a pharmacoepidemiologic cohort study in the largest integrated healthcare system in the US. Spironolactone dose-dependently reduced the intake of sweetened or unsweetened alcohol solutions in male and female mice. No effects of spironolactone were observed on drinking of a sweet solution without alcohol, food or water intake, motor coordination, alcohol-induced ataxia, or blood alcohol levels. Spironolactone dose-dependently reduced operant alcohol self-administration in dependent and nondependent male and female rats. In humans, a greater reduction in alcohol consumption was observed among those who received spironolactone, compared to propensity score-matched individuals who did not receive spironolactone. The largest effects were among those who reported hazardous/heavy episodic alcohol consumption at baseline (AUDIT-C ≥ 8) and those exposed to ≥ 50 mg/day of spironolactone. These convergent findings across rodent and human studies demonstrate that spironolactone reduces alcohol use and support the hypothesis that this medication may be further studied as a novel pharmacotherapy for AUD.
This is a preview of subscription content, access via your institution
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Heilig M, MacKillop J, Martinez D, Rehm J, Leggio L, Vanderschuren L. Addiction as a brain disease revised: why it still matters, and the need for consilience. Neuropsychopharmacology 2021;46:1715–1723.
Witkiewitz K, Litten RZ, Leggio L. Advances in the science and treatment of alcohol use disorder. Sci Adv. 2019;5:eaax4043.
Addolorato G, Leggio L, Hillemacher T, Kraus T, Jerlhag E, Bleich S. Hormones and drinking behaviour: new findings on ghrelin, insulin, leptin and volume-regulating hormones. An ESBRA Symposium report. Drug Alcohol Rev. 2009;28:160–165.
Kenna GA, Swift RM, Hillemacher T, Leggio L. The relationship of appetitive, reproductive and posterior pituitary hormones to alcoholism and craving in humans. Neuropsychol Rev. 2012;22:211–228.
Funder JW. Mineralocorticoid receptors: distribution and activation. Heart Fail Rev. 2005;10:15–22.
Molinari AM, Machado-Rada MY, Mazaira GI, Erlejman AG, Galigniana MD. Molecular basis of mineralocorticoid receptor action in the nervous system. CNS Neurol Disord Drug Targets. 2013;12:1163–1174.
Kellner M, Wiedemann K. Mineralocorticoid receptors in brain, in health and disease: possibilities for new pharmacotherapy. Eur J Pharmacol. 2008;583:372–378.
Reul JM, Gesing A, Droste S, Stec IS, Weber A, Bachmann C, et al. The brain mineralocorticoid receptor: greedy for ligand, mysterious in function. Eur J Pharmacol. 2000;405:235–249.
Wingenfeld K, Otte C. Mineralocorticoid receptor function and cognition in health and disease. Psychoneuroendocrinology 2019;105:25–35.
de Kloet ER, Rots NY, van den Berg DT, Oitzl MS. Brain mineralocorticoid receptor function. Ann N Y Acad Sci. 1994;746:8–20.
Dorey R, Piérard C, Shinkaruk S, Tronche C, Chauveau F, Baudonnat M, et al. Membrane mineralocorticoid but not glucocorticoid receptors of the dorsal hippocampus mediate the rapid effects of corticosterone on memory retrieval. Neuropsychopharmacology 2011;36:2639–2649.
Zhou M, Kindt M, Joëls M, Krugers HJ. Blocking mineralocorticoid receptors prior to retrieval reduces contextual fear memory in mice. PLoS ONE. 2011;6:e26220.
Gomez-Sanchez E, Gomez-Sanchez CE. The multifaceted mineralocorticoid receptor. Compr Physiol. 2014;4:965–994.
Mitra R, Ferguson D, Sapolsky RM. Mineralocorticoid receptor overexpression in basolateral amygdala reduces corticosterone secretion and anxiety. Biol Psychiatry. 2009;66:686–690.
de Kloet ER, Otte C, Kumsta R, Kok L, Hillegers MH, Hasselmann H, et al. Stress and depression: a crucial role of the mineralocorticoid receptor. J Neuroendocrinol. 2016;28:1–12.
Vogel S, Fernández G, Joëls M, Schwabe L. Cognitive adaptation under stress: a case for the mineralocorticoid receptor. Trends Cogn Sci. 2016;20:192–203.
Cannavo A, Bencivenga L, Liccardo D, Elia A, Marzano F, Gambino G, et al. Aldosterone and mineralocorticoid receptor system in cardiovascular physiology and pathophysiology. Oxid Med Cell Longev. 2018;2018:1204598–1204598.
Leggio L, Ferrulli A, Cardone S, Miceli A, Kenna GA, Gasbarrini G, et al. Renin and aldosterone but not the natriuretic peptide correlate with obsessive craving in medium-term abstinent alcohol-dependent patients: a longitudinal study. Alcohol. 2008;42:375–381.
Aoun EG, Jimenez VA, Vendruscolo LF, Walter NAR, Barbier E, Ferrulli A, et al. A relationship between the aldosterone–mineralocorticoid receptor pathway and alcohol drinking: preliminary translational findings across rats, monkeys and humans. Mol Psychiatry. 2018;23:1466–1473.
Fahlke C, Hård E, Eriksson CJ, Engel JA, Hansen S. Consequence of long-term exposure to corticosterone or dexamethasone on ethanol consumption in the adrenalectomized rat, and the effect of type I and type II corticosteroid receptor antagonists. Psychopharmacology 1995;117:216–224.
Fahlke C, Hård E, Hansen S. Facilitation of ethanol consumption by intracerebroventricular infusions of corticosterone. Psychopharmacology 1996;127:133–139.
O’Callaghan MJ, Croft AP, Jacquot C, Little HJ. The hypothalamopituitary-adrenal axis and alcohol preference. Brain Res Bull. 2005;68:171–178.
Koenig HN, Olive MF. The glucocorticoid receptor antagonist mifepristone reduces ethanol intake in rats under limited access conditions. Psychoneuroendocrinology. 2004;29:999–1003.
Tunstall BJ, Vendruscolo LF, Allen–Worthington K. Chapter 26 - Rat models of alcohol use disorder. In: Suckow MA, Hankenson FC, Wilson RP, Foley PL, editors. The laboratory rat (3rd Edition). Cambridge, MA, USA: Academic Press; 2020. p. 967–986.
Kashkin VA, Shekunova EV, Egorov AY, Bagrov AY. Marinobufagenin in urine: a potential marker of predisposition to ethanol and a target for spironolactone. Curr Hypertens Rev. 2018;14:35–38.
Makhijani VH, Van Voorhies K, Besheer J. The mineralocorticoid receptor antagonist spironolactone reduces alcohol self-administration in female and male rats. Pharmacol Biochem Behav. 2018;175:10–18.
Makhijani VH, Irukulapati P, Van Voorhies K, Fortino B, Besheer J. Central amygdala mineralocorticoid receptors modulate alcohol self-administration. Neuropharmacology 2020;181:108337.
Palzes VA, Farokhnia M, Kline-Simon AH, Elson J, Sterling S, Leggio L, et al. Effectiveness of spironolactone dispensation in reducing weekly alcohol use: a retrospective high-dimensional propensity score-matched cohort study. Neuropsychopharmacology. 2021;46:2140–2147.
Rhodes JS, Best K, Belknap JK, Finn DA, Crabbe JC. Evaluation of a simple model of ethanol drinking to intoxication in C57BL/6J mice. Physiol Behav. 2005;84:53–63.
McGinn MA, Tunstall BJ, Schlosburg JE, Gregory-Flores A, George O, de Guglielmo G, et al. Glucocorticoid receptor modulators decrease alcohol self-administration in male rats. Neuropharmacology 2021;188:108510.
Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7:27–31.
Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med. 1998;158:1789–1795.
Fiellin DA, Reid MC, O’Connor PG. Screening for alcohol problems in primary care: a systematic review. Arch Intern Med. 2000;160:1977–1989.
Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Sturmer T. Variable selection for propensity score models. Am J Epidemiol. 2006;163:1149–1156.
Pearl J. Invited commentary: understanding bias amplification. Am J Epidemiol. 2011;174:1223–1227.
Cormen TH. Introduction to algorithms. Cambridge, MA: MIT Press; 2009.
Donald SG, Lang K. Inference with difference-in-differences and other panel data. Rev Econ Stat. 2007;89:221–233.
Lechner M. The estimation of causal effects by difference-in-difference methods. Found Trends® Econ. 2011;4:165–224.
Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28:3083–3107.
Understanding binge drinking. https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/binge-drinking.
Berger S, Wolfer DP, Selbach O, Alter H, Erdmann G, Reichardt HM, et al. Loss of the limbic mineralocorticoid receptor impairs behavioral plasticity. Proc Natl Acad Sci USA. 2006;103:195–200.
Grupp LA, Elias J, Perlanski E, Stewart RB. Modification of ethanol-induced motor impairment by diet, diuretic, mineralocorticoid, or prostaglandin synthetase inhibitor. Psychopharmacology 1985;87:20–24.
Vendruscolo LF, Roberts AJ. Operant alcohol self-administration in dependent rats: focus on the vapor model Alcohol. 2014;48:277–286.
Zorrilla EP, Logrip ML, Koob GF. Corticotropin releasing factor: a key role in the neurobiology of addiction. Front Neuroendocrinol. 2014;35:234–244.
Roberto M, Spierling SR, Kirson D, Zorrilla EP. Corticotropin-releasing factor (CRF) and addictive behaviors. Int Rev Neurobiol. 2017;136:5–51.
Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58:295–300.
Shimonovich M, Pearce A, Thomson H, Keyes K, Katikireddi SV. Assessing causality in epidemiology: revisiting Bradford Hill to incorporate developments in causal thinking. Eur J Epidemiol. 2021;36:873–887.
Meeks TW, Bekman NM, Lanouette NM, Yung KA, Vienna RP. Alcohol and alcohol use disorder. In: Ritchie EC, Llorente MD, editors. Veteran psychiatry in the US: optimizing clinical outcomes. Cham: Springer International Publishing; 2019. p. 135–56.
Rubinsky AD, Kivlahan DR, Volk RJ, Maynard C, Bradley KA. Estimating risk of alcohol dependence using alcohol screening scores. Drug Alcohol Depend. 2010;108:29–36.
Harris AHS, Bradley KA, Bowe T, Henderson P, Moos R. Associations between AUDIT-C and mortality vary by age and sex. Popul Health Manag. 2010;13:263–268.
Kovács GL. The role of atrial natriuretic peptide in alcohol withdrawal: a peripheral indicator and central modulator? Eur J Pharmacol. 2000;405:103–112.
Sonino N, Fallo F, Fava GA. Psychological aspects of primary aldosteronism. Psychother Psychosom. 2006;75:327–330.
Sonino N, Tomba E, Genesia ML, Bertello C, Mulatero P, Veglio F, et al. Psychological assessment of primary aldosteronism: a controlled study. J Clin Endocrinol Metab. 2011;96:E878–883.
Hlavacova N, Jezova D. Chronic treatment with the mineralocorticoid hormone aldosterone results in increased anxiety-like behavior. Horm Behav. 2008;54:90–97.
Farokhnia M, Browning BD, Leggio L. Prospects for pharmacotherapies to treat alcohol use disorder: an update on recent human studies. Curr Opin Psychiatry. 2019;32:255–265.
Smythe JW, Murphy D, Timothy C, Costall B. Hippocampal mineralocorticoid, but not glucocorticoid, receptors modulate anxiety-like behavior in rats. Pharm Biochem Behav. 1997;56:507–513.
Korte SM, de Boer SF, de Kloet ER, Bohus B. Anxiolytic-like effects of selective mineralocorticoid and glucocorticoid antagonists on fear-enhanced behavior in the elevated plus-maze. Psychoneuroendocrinology 1995;20:385–394.
Calvo N, Volosin M. Glucocorticoid and mineralocorticoid receptors are involved in the facilitation of anxiety-like response induced by restraint. Neuroendocrinology 2001;73:261–271.
Ding H, Cui SY, Cui XY, Liu YT, Hu X, Zhao HL, et al. Anti-stress effects of combined block of glucocorticoid and mineralocorticoid receptors in the paraventricular nucleus of the hypothalamus. Br J Pharmacol. 2021;178:3696–3707.
Watts AG, Sanchez-Watts G. Region-specific regulation of neuropeptide mRNAs in rat limbic forebrain neurones by aldosterone and corticosterone. J Physiol. 1995;484:721–736.
de Guglielmo G, Kallupi M, Pomrenze MB, Crawford E, Simpson S, Schweitzer P, et al. Inactivation of a CRF-dependent amygdalofugal pathway reverses addiction-like behaviors in alcohol-dependent rats. Nat Commun. 2019;10:1238.
Vendruscolo LF, Koob GF. Alcohol dependence conceptualized as a stress disorder. In: Harkness KL, Hayden EP, editors. The Oxford handbook of stress and mental health. Oxford, United Kingdom: Oxford University Press; 2020.
van Eekelen JA, Bohn MC, de Kloet ER. Postnatal ontogeny of mineralocorticoid and glucocorticoid receptor gene expression in regions of the rat tel- and diencephalon. Brain Res Dev Brain Res. 1991;61:33–43.
Yongue BG, Roy EJ. Endogenous aldosterone and corticosterone in brain cell nuclei of adrenal-intact rats: regional distribution and effects of physiological variations in serum steroids. Brain Res. 1987;436:49–61.
Vendruscolo LF, Estey D, Goodell V, Macshane LG, Logrip ML, Schlosburg JE, et al. Glucocorticoid receptor antagonism decreases alcohol seeking in alcohol-dependent individuals. J Clin Investig. 2015;125:3193–3197.
Joëls M, de Kloet ER. 30 Years of the mineralocorticoid receptor: the brain mineralocorticoid receptor: a saga in three episodes. J Endocrinol. 2017;234:T49–t66.
Yau JL, Noble J, Seckl JR. Continuous blockade of brain mineralocorticoid receptors impairs spatial learning in rats. Neurosci Lett. 1999;277:45–48.
Douma BR, Korte SM, Buwalda B, la Fleur SE, Bohus B, Luiten PG. Repeated blockade of mineralocorticoid receptors, but not of glucocorticoid receptors impairs food rewarded spatial learning. Psychoneuroendocrinology 1998;23:33–44.
Thai CA, Zhang Y, Howland JG. Effects of acute restraint stress on set-shifting and reversal learning in male rats. Cogn Affect Behav Neurosci. 2013;13:164–173.
Otte C, Moritz S, Yassouridis A, Koop M, Madrischewski AM, Wiedemann K, et al. Blockade of the mineralocorticoid receptor in healthy men: effects on experimentally induced panic symptoms, stress hormones, and cognition. Neuropsychopharmacology 2007;32:232–238.
Young KD, Preskorn SH, Victor T, Misaki M, Bodurka J, Drevets WC. The effect of mineralocorticoid and glucocorticoid receptor antagonism on autobiographical memory recall and amygdala response to implicit emotional stimuli. Int J Neuropsychopharmacol 2016;19:pyw036.
Wingenfeld K, Kuehl LK, Dziobek I, Roepke S, Otte C, Hinkelmann K. Effects of mineralocorticoid receptor blockade on empathy in patients with major depressive disorder. Cogn Affect Behav Neurosci. 2016;16:902–910.
Klok MD, Alt SR, Irurzun Lafitte AJ, Turner JD, Lakke EA, Huitinga I, et al. Decreased expression of mineralocorticoid receptor mRNA and its splice variants in postmortem brain regions of patients with major depressive disorder. J Psychiatr Res. 2011;45:871–878.
Seckl JR, Fink G. Antidepressants increase glucocorticoid and mineralocorticoid receptor mRNA expression in rat hippocampus in vivo. Neuroendocrinology 1992;55:621–626.
Otte C, Hinkelmann K, Moritz S, Yassouridis A, Jahn H, Wiedemann K, et al. Modulation of the mineralocorticoid receptor as add-on treatment in depression: a randomized, double-blind, placebo-controlled proof-of-concept study. J Psychiatr Res. 2010;44:339–346.
Otte C, Wingenfeld K, Kuehl LK, Kaczmarczyk M, Richter S, Quante A, et al. Mineralocorticoid receptor stimulation improves cognitive function and decreases cortisol secretion in depressed patients and healthy individuals. Neuropsychopharmacology 2015;40:386–393.
Vendruscolo LF, Terenina-Rigaldie E, Raba F, Ramos A, Takahashi RN, Mormède P. Evidence for a female-specific effect of a chromosome 4 locus on anxiety-related behaviors and ethanol drinking in rats. Genes Brain Behav. 2006;5:441–450.
de Kloet ER, Meijer OC, de Nicola AF, de Rijk RH, Joëls M. Importance of the brain corticosteroid receptor balance in metaplasticity, cognitive performance and neuro-inflammation. Front Neuroendocrinol. 2018;49:124–145.
de Gasparo M, Joss U, Ramjoué HP, Whitebread SE, Haenni H, Schenkel L, et al. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther. 1987;240:650–656.
Kolkhof P, Bärfacker L. 30 Years of the mineralocorticoid receptor: mineralocorticoid receptor antagonists: 60 years of research and development. J Endocrinol. 2017;234:T125–T140.
Dinh QN, Young MJ, Evans MA, Drummond GR, Sobey CG, Chrissobolis S. Aldosterone-induced oxidative stress and inflammation in the brain are mediated by the endothelial cell mineralocorticoid receptor. Brain Res. 2016;1637:146–153.
Penuela S, Gehi R, Laird DW. The biochemistry and function of pannexin channels. Biochim Biophys Acta. 2013;1828:15–22.
Good ME, Chiu Y-H, Poon IKH, Medina CB, Butcher JT, Mendu SK, et al. Pannexin 1 channels as an unexpected new target of the anti-hypertensive drug spironolactone. Circ Res. 2018;122:606–615.
Tunstall BJ, Lorrai I, McConnell SA, Gazo KL, Zallar LJ, de Guglielmo G, et al. Probenecid reduces alcohol drinking in rodents. is pannexin1 a novel therapeutic target for alcohol use disorder? Alcohol Alcohol. 2019;54:497–502.
Leggio L, Lee MR. Treatment of alcohol use disorder in patients with alcoholic liver disease. Am J Med. 2017;130:124–134.
Farinelli LA, Piacentino D, Browning BD, Brewer BB, Leggio L. Cardiovascular consequences of excessive alcohol drinking via electrocardiogram: a systematic review. J Addict Nurs. 2021;32:39–45.
Vuittonet CL, Halse M, Leggio L, Fricchione SB, Brickley M, Haass-Koffler CL, et al. Pharmacotherapy for alcoholic patients with alcoholic liver disease. Am J Health Syst Pharm. 2014;71:1265–1276.
Mirijello A, Tarli C, Vassallo GA, Sestito L, Antonelli M, d’Angelo C, et al. Alcoholic cardiomyopathy: what is known and what is not known. Eur J Intern Med. 2017;43:1–5.
Martinotti G, Di Nicola M, Tedeschi D, Callea A, Di Giannantonio M, Janiri L. Craving Typology Questionnaire (CTQ): a scale for alcohol craving in normal controls and alcoholics. Compr Psychiatry. 2013;54:925–932.
Addolorato G, Leggio L, Abenavoli L, Gasbarrini G. Neurobiochemical and clinical aspects of craving in alcohol addiction: a review. Addict Behav. 2005;30:1209–1224.
Leggio L, Kenna GA, Fenton M, Bonenfant E, Swift RM. Typologies of alcohol dependence. From Jellinek to genetics and beyond. Neuropsychol Rev. 2009;19:115–129.
The authors would like to thank all staff involved in data collection, management, and support at the National Institutes of Health Intramural Research Program (NIH IRP) and the following joint post-baccalaureate fellows in the NIDA/NIAAA Clinical Psychoneuroendocrinology and Neuropsychopharmacology and NIDA Neurobiology of Addiction Sections: Brandon Blank, Adriana Gregory-Flores, Claire Pince, and Lia Zallar. The authors would also like to thank Dr. Kendall Bryant (NIAAA) for providing administrative support and guidance during the initial development of the human pharmacoepidemiology study. Finally, the authors would like to thank Dr. Gail Seabold (NIDA) for professional proofreading and editing the manuscript.
This work was supported by the NIH intramural funding ZIA-DA-000635 and ZIA-AA000218 (Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section – PI: LL), ZIA-DA000602–06 (Neurobiology of Addiction Section – PI: GFK), and NIAAA extramural funding (R01-AA023733, U24-AA020794, U01-AA020790, and U10-AA013566). The content of this article is solely the responsibility of the authors and does not necessarily represent the official view of the funding agencies.
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Farokhnia, M., Rentsch, C.T., Chuong, V. et al. Spironolactone as a potential new pharmacotherapy for alcohol use disorder: convergent evidence from rodent and human studies. Mol Psychiatry (2022). https://doi.org/10.1038/s41380-022-01736-y